Cure My Disease

Don't miss your cure!

 Log in / Sign up

Muscle-Saving app: a new weapon in the GLP-1 weight loss battle?

NCT ID NCT07787533

Disease control Sponsor: Louisiana State University and A&M College Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time

Summary

This study tests a 12-week app-based strength training program called PLAN-RT 1.0, designed for midlife women (ages 40-54) who recently started GLP-1 medication for weight loss. The goal is to see if the program is practical and acceptable, and whether it can help preserve muscle strength and function while promoting regular exercise habits. Researchers will measure enrollment, retention, satisfaction, and early changes in strength and body composition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A 12-week app-delivered resistance training program (PLAN-RT 1.0) with behavior change techniques
What this could lead to
If successful, this program could offer a scalable way to help women on GLP-1 medications preserve muscle and build lasting exercise habits, potentially improving long-term health outcomes.
What could go wrong
This is a small early-stage study (15 participants) focused on feasibility, not proof of effectiveness. Results may not generalize, and the program's success depends on user adherence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2026

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 59 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Participants must meet all of the following criteria: * Female, age 40 to 54 years. * Recently initiated GLP-1 receptor agonist (GLP-1RA) therapy within the past 6 months. * Body mass index (BMI) ≥27 kg/m². * Not currently participating in regular resistance training (self-reported absence of regular resistance training during the previous month). * Able to stand, sit, and perform bodyweight movements without assistive devices. * Owns a compatible smartphone (iOS or Android) with cellular or Wi-Fi access and is willing to use study applications. * Able to read, understand, and provide informed consent in English. * Willing and able to attend required in-person study visits. Exclusion Criteria: Participants will be excluded if they meet any of the following criteria: * Plans to discontinue GLP-1RA therapy or substantially modify treatment during the 12-week study period. * Self-reported musculoskeletal injury, orthopedic limitation, or surgery within the previous 6 months that would contraindicate resistance training participation. * Self-reported unstable cardiovascular disease or cardiac event within the previous 6 months. * Currently pregnant or planning to become pregnant during the study period. * Active eating disorder or psychiatric condition that may interfere with study participation. * Unable to use smartphone applications required for the intervention. * Current participation in another pharmacological, behavioral, weight management, or chronic disease management program that could confound study outcomes.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Behavior change are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Behavior change Digital intervention GLP1 agonist Obesity & overweight Perimenopausal women Resistance exercise Women's health

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Louisiana State University School of Kinesiology

    Baton Rouge, Louisiana, 70803, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.